Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.
Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration in bioprosthetic aortic valves with the company’s innovative RESILIA tissue.
SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.
After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions.
The FDA’s agenda includes an advisory committee meeting for Sarepta’s delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy.
FDA Action Alert: Sarepta, Protalix, Otsuka/Lundbeck and More Read More »
The FDA’s new guidance on decentralized clinical trials clarifies how investigators and trial sponsors can use digital health technologies and involve primary healthcare practitioners.
FDA Guidance May Bolster Confidence in Decentralized Clinical Trials Read More »
Despite multiple therapeutics approved to treat localized symptoms, there are currently no systemic therapies on the market for Sjogren’s syndrome.
Opinion: Hope on the Horizon for Sjogren’s Syndrome Read More »
La lipotoxicidad, el aumento del estrés oxidativo y la disfunción mitocondrial son varios de los mecanismos implicados.
Fisiopatología y nuevas terapias | Miocardiopatía diabética Read More »
La sostenibilidad es uno de los grandes retos de la sociedad actual y para su consecución se han puesto sobre la mesa todas las herramientas y esfuerzos disponibles. Esta urgencia llega en una etapa en la que las nuevas tecnologías han impregnado una buena parte de las relaci …
Cómo la digitalización puede ayudar a potenciar el desarrollo sostenible Read More »
The restructuring, along with reductions in discretionary spending, are expected to save the company $17 million to $20 million by 2024.
ZimVie will lay off 5% of staff in bid to reduce costs, streamline business Read More »
